Botswana
Diabetes country report 2011 — 2050
Number of adults (20–79 years) with diabetes in Botswana (BW)
2011 | 93.9 thousand |
2024 | 58.2 thousand |
2050 | 118.6 thousand |
Botswana is one of the 49 countries and territories in the IDF Africa Region.
Data source(s) used for the diabetes estimates in adults:
- Ministry of Health Botswana, WHO STEPS, 2007.
- Gobopamang Letamo et al. Int Health. 2017 Jan;9(1):11-19. doi: 10.1093/inthealth/ihw052. Epub 2016 Dec 9. PMID: 27940479
- Ministry of Health Republic of Botswana, WHO STEPS 2014
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | - | 93.9 | 58.2 | 118.6 |
Age-standardised prevalence of diabetes, % | - | 10.8 | 4.6 | 5.4 |
Proportion of people with undiagnosed diabetes, % | - | - | 60.5 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 35.2 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 67.1 | 120.8 |
Age-standardised prevalence of IFG, % | - | - | 4.6 | 5.1 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 84.0 | 110.1 | 197.8 |
Age-standardised prevalence of IGT, % | - | 8.8 | 7.6 | 8.4 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 1,252.0 | 353.0 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 3.7 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | - | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | - | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | - | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | - | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 131.7 | 216.5 |
Total diabetes-related health expenditure, ID million | - | - | 296.8 | 488.1 |
Diabetes-related health expenditure per person, USD | - | 816.0 | 2,261.4 | 1,825.2 |
Diabetes-related health expenditure per person, ID | - | - | 5,097.9 | 4,114.5 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 1,330.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 220.9 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | - | 1,146.9 | 1,580.9 | 2,479.3 |
Population of children and adolescents (0-19 y) | - | - | 1,055,264.0 | - |
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | - |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | - |
Population of children and adolescents (0-19 y) | - |